Canada tests Ebola mRNA vaccine in Congo
Canada has launched a Phase I clinical trial for an mRNA-based vaccine against Ebola virus disease caused by the Bundibugyo virus, aiming to assess its safety and immune response. The initiative comes in response to an outbreak in the Democratic Republic of the Congo, where the World Health Organization reported 3,605 cases and 1,587 deaths by the end of July, marking the largest outbreak ever recorded in the country's history. Adult volunteers aged between 18 and 65 will not be injected with the virus itself, and safe dosage levels and potential side effects will be determined before proceeding to later stages. Canada is the second country after the United Kingdom to approve a clinical trial for this vaccine, reflecting ongoing efforts to develop treatment and preventive measures for a disease that currently has no licensed vaccine.
Notice: This Is an AI-Generated Summary
Comments (0)